pyrrolomycin d

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyrrolomycin D: from Streptomyces strain SF-2080; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	133780
CHEMBL ID	4101922
MeSH ID	M0106751

Synonyms (8)

Synonym
antibiotic sf 2080d
(3,5-dichloro-2-hydroxyphenyl)(3,4,5-trichloro-1h-pyrrol-2-yl)methanone
methanone, (3,5-dichloro-2-hydroxyphenyl)(3,4,5-trichloro-1h-pyrrol-2-yl)-
sf 2080d
pyrrolomycin d
81910-07-8
DTXSID90231462
CHEMBL4101922

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay ID	Title	Year	Journal	Article
AID1530241	Antibiofilm activity against Staphylococcus aureus isolate 657 at 1.5 ug/ml relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
AID1530238	Antibiofilm activity against Staphylococcus aureus ATCC 29213 at 1.5 ug/ml relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
AID1471337	Inhibition of biofilm formation in Staphylococcus aureus ATCC 29213 at 1.5 ug/ml after 24 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1471344	Inhibition of biofilm formation in Staphylococcus epidermidis RP62A at 1.5 ug/ml after 24 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1471340	Inhibition of biofilm formation in Staphylococcus aureus ATCC 25923 at 1.5 ug/ml after 24 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1530239	Antibiofilm activity against Staphylococcus epidermidis DSM 3269 at 1.5 ug/ml relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
AID1471342	Inhibition of biofilm formation in Staphylococcus aureus ATCC 702 at 1.5 ug/ml after 24 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1471343	Inhibition of biofilm formation in Staphylococcus epidermidis DSM 3269 at 1.5 ug/ml after 24 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1530237	Antibiofilm activity against Staphylococcus aureus ATCC 25923 at 1.5 ug/ml relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
AID1530240	Antibiofilm activity against Staphylococcus epidermidis RP62A at 1.5 ug/ml relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
AID1471341	Inhibition of biofilm formation in Staphylococcus aureus ATCC 657 at 1.5 ug/ml after 24 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1530242	Antibiofilm activity against Staphylococcus aureus isolate 702 at 1.5 ug/ml relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (66.67)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (33.33)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.38 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.32 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (16.67%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.15	1	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.88	4	pyrrole; secondary amine
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	1.96	1
tazobactam Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.	2.15	1	penicillanic acids; triazoles	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
pyrrolomycin a pyrrolomycin A: chlorinated nitropyrrole from Actinomycetes strain SF-2080; structure given in first source. pyrrolomycin A : A member of the class of pyrroles that is 1H-pyrrole which is substituted by chloro groups at positions 2 and 3 and by a nitro group position 4. It is the simplest member of the pyrrolomycins, a family of natural products found in several species of the Streptomyces genus. The compound is active against Gram-positive and Gram-negative bacteria and some genera of fungi.	1.96	1	antibiotic antifungal agent; C-nitro compound; organochlorine compound; pyrroles	antibacterial agent; bacterial metabolite
pyrrolomycin c pyrrolomycin C: from Streptomyces strain SF-2080; structure given in first source	2.88	4
phenylalanine arginine beta-naphthylamide phenylalanine arginine beta-naphthylamide: a drug efflux pump inhibitor; structure in first source	2.15	1	peptide
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	1.96	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
1-(1-naphthylmethyl)piperazine [no description available]	2.15	1
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	2.15	1	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
oroidin oroidin: from marine sponges of the genus Agelas; structure in first source	3.31	1	pyrroles; secondary carboxamide	metabolite
nxl 104 avibactam sodium : An organic sodium salt that is the monosodium salt of avibactam. Used in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.	2.15	1	organic sodium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
rpx7009 RPX7009: a beta-lactamase inhibitor; structure in first source	2.15	1

Condition	Relationship Strength	Studies
Infections, Pseudomonas [description not available]	2.15	1
Cronobacter Infections [description not available]	2.15	1
Enterobacteriaceae Infections Infections with bacteria of the family ENTEROBACTERIACEAE.	2.15	1
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	2.15	1
Extravascular Hemolysis [description not available]	1.96	1
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	1.96	1

chemdatabank.com